Advertisement

Comparison between Paf-Acether Receptors on Intact Washed Human Platelets and Human Endothelial Cells in Culture

  • Ruth Korth
  • M. Hirafuji
  • J. Bidault
  • B. Canton
  • F. Russo-Marie
  • J. Benveniste

Abstract

Paf-acether (paf, formerly platelet-activating factor) (Benveniste et al., 1972), with the structure 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine (Benveniste et al., 1979; Demopoulos et al., 1979; Blank et al., 1979), is a biologically active phospholipid which is released by several cell types upon stimulation (for review Pinckard et al., 1982; Vargaftig et al., 1981). The mediator activates platelets, polymorphonuclear neutrophils, macrophages and endothelial cells most probably via a receptor-dependent pathway (Valone et al., 1982; Valone and Goetzl 1983; Lambrecht and Parnham, 1986; Korth et al., 1987; Valone, 1988). Serum albumin acts as a necessary phospholipid carrier for both paf release (Benveniste, J. et al., 1972; Benveniste, J., 1974) and specific paf binding (Korth and Benveniste, 1987) and seems to inhibit the pafdegrading enzyme, acetylhydrolase (Wardlow et al., 1986). Different specific antagonists, such as the paf analogue CV 3988 (Terashita et al., 1983), the naturally occurring kad-surenone (Shen et al., 1985) and Ginkgolides (Nunez et al., 1986; Korth and Benveniste, 1987; Korth et al., 1988 c; Braquet and Godfroid, 1987), as well as synthetic hetrazepines and calcium-blocking agents, inhibited platelet activation and paf binding (Casals-Stenzel and Weber, 1987; Korth et al., 1987 and 1988 b; Wade et al., 1986). Binding studies with radiolabeled antagonists supported the existence of paf receptors in platelets (Hwang et al., 1986 a). A close correlation between inhibition of paf-induced platelet aggregation and binding of labelled paf suggested the importance of the putative paf receptor for platelet activation (Korth et al., 1988 c). Paf receptors were coupled with modulation of phospholipase C activity (Morrison and Shukla, 1988).

Keywords

Human Platelet Human Endothelial Cell Rabbit Platelet Bovine Pulmonary Artery Endothelial Cell Intact Human Platelet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benveniste, J. Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature. 249:581–583, 1974.PubMedCrossRefGoogle Scholar
  2. Benveniste, J., Henson, P.M. and Cochrane, C.G. Leukocyte-dependent histamine release from rabbit platelets: The role of Ig E, basophils and platelet-activating factor. J. Exp. Med. 136:1356–1377, 1972.PubMedCrossRefGoogle Scholar
  3. Benveniste, J., Tence, M., Varenne, P., Bidault, J., Boullet, C., and Polonsky, J. Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acéther, un alkyl ether analogue de la lysophosphatidylcholine. C.R. Acad. Sci. Paris. 289:1037–1040, 1979.Google Scholar
  4. Blank, M.L., Snyder, F., Byers, L.W., Brooks, B. And Muirhead, E.E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem. Biophys. Res. Commun. 90: 1194–1200, 1979.PubMedCrossRefGoogle Scholar
  5. Blank M.L., Spector, A.A., Kaduce, T.L., Lee, T.C. and Snyder, F. Metabolism of platelet-activating factor (l-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and 1-alkyl-2-acetyl-sn-glycerol by human endothelial cells. Biochim. Biophys. Acta. 876:373–378, 1986.PubMedCrossRefGoogle Scholar
  6. Braquet, P. and Godfroid, J.J. Conformational properties of the paf-acether receptor in platelets based on structure activity studies. In: Platelet-Activating Factor. ed. by F. Snyder. New York, Plenum Press, p. 191–236, 1987.CrossRefGoogle Scholar
  7. Brock, T.A. and Gimbrone, Jr., M.A. Platelet activating factor alters calcium homeostasis in cultured vascular endothelial cells. Am. J. Physiol. 250:H1086–H1092, 1986.PubMedGoogle Scholar
  8. Bussolino, F., Aglietta, M., Sanavio, F., Stachini, A., Lauri, D. and Camussi, G. Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. J. Immunol. 135:2748–2753, 1985.PubMedGoogle Scholar
  9. Bussolino, F., Breviario, F., Tetta, C., Aglietta, M., Mantovani, A. and Dejana, E. Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J. Clin. Invest. 77:2027–2033, 1986.PubMedCrossRefGoogle Scholar
  10. Casals-Stenzel, J. and Weber, K.H. Triazolodiazepines: dissociation of their Paf (platelet-activating factor) antagonistic and CNS activity. Br. J. Pharmacol. 90:139–146, 1987.PubMedCrossRefGoogle Scholar
  11. Casals-Stenzel, J., Franke, J., Friedrich, T. and Lichey, J. Bronchial and vascular effects of paf in rat isolated lung are completely blocked by WEB 2086, a novel specific Paf antagonist. Br. J. Pharmacol. 91:799–802, 1987.PubMedCrossRefGoogle Scholar
  12. Chilton, F.H., O’Flaherty, J.T., Ellis, J.M., Swendsen, C.L. and Wykle, R.L. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. J. Biol Chem. 258: 7268–7271, 1983a.PubMedGoogle Scholar
  13. Chilton, F.H., O’Flaherty, J.T., Ellis, J.M., Swendsen, C.L. and Wykle, R.L. Metabolic fate of platelet-activating factor in neutrophils. J. Biol. Chem. 258:6357–6361, 1983b.PubMedGoogle Scholar
  14. Demopoulos, C.A., Pinckard, R.N. and Hanahan, D.J. Platelet-activating factor: evidence for 1-O-alkyl-2-acetyl-sn-glycerol-3-phosphorylcholine as the active component (a new class of lipid mediators). J. Biol Chem. 254:9355–9358, 1979.PubMedGoogle Scholar
  15. D’Humiere, S.D., Russo-Marie, F. and Vargaftig, B.B. Paf-acether-induced synthesis of prostacyclin by human endothelial cells. Eur. J. Pharmacol. 131:13–19, 1986.CrossRefGoogle Scholar
  16. Doyle, V.M., Creba, J.A. and Rüegg, U.T. Platelet-activating factor mobilises intracellular calcium in vascular smooth muscle cells. FEBS Letter. 197:13–16, 1986.CrossRefGoogle Scholar
  17. Emeis, J.J. and Kluft, C. PAF-acether-induced release of tissue type plasminogen activator factor from vessel walls. Blood. 66:86–91, 1985.PubMedGoogle Scholar
  18. Farr, R.S., Cox, C.P., Wardlow, M.L. and Jorgensen, R. Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). Clin. Immunol. Immunopathol. 15:318–330, 1980.PubMedCrossRefGoogle Scholar
  19. Grigorian, G.Y. and Ryan, U.S. Platelet-activating factor effects on bovine pulmonary artery endothelial cells. Circul. Res. 61:389–395, 1987.CrossRefGoogle Scholar
  20. Hirafuji, M., Mencia-Huerta, J.M. and Benveniste, J. Regulation of PAF-acether (platelet-activating factor) biosynthesis in cultured human vascular endothelial cells stimulated with thrombin. Biochim. Biophys. Acta. 930:359–369, 1987.PubMedCrossRefGoogle Scholar
  21. Hwang, S.B., Lam, M.H. and Chang, M.N. Specific binding of 3H-dihydrokadsurenone to rabbit platelet membranes and its inhibition by the receptor agonists and antagonists of platelet-activating factor. J. Biol. Chem. 261:13720–13726, 1986 a.PubMedGoogle Scholar
  22. Hwang, S.B., Lam, M.H., Li, C.L. and Shen, T.Y. Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema. Eur. J. Pharmacol. 120:33–41, 1986 b.PubMedCrossRefGoogle Scholar
  23. Jaffe, E.A., Nachmann, R.L., Becker, C.G. and Minick, C.R. Culture of human endothelial cells. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52:2745–2756, 1973.PubMedCrossRefGoogle Scholar
  24. Kimani, G., Tonnesen, M.G. and Henson, P.M. Stimulation of eosinophil adherence to human vascular endothelial cells in vitro by platelet-activating factor. J. Immunol. 140:3161–3166, 1988.PubMedGoogle Scholar
  25. Kloprogge, E., Mommersteeg, M., and Akkerman, J.W. Kinetics of platelet-activating factor (1–0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) induced fibrinogen binding to human platelets. J. Biol Chem. 261:11071–11076, 1986.PubMedGoogle Scholar
  26. Korth, R. and Benveniste, J. BN 52021 displaces 3H-paf-acether from and inhibits its binding to intact human platelets. Eur. J. Pharmacol. 142:331–341, 1987.PubMedCrossRefGoogle Scholar
  27. Korth, R., Bidault, J., Leyravaud, S., Ninio, E. and Benveniste, J. Washed human platelets and whole blood cells do not catabolize paf-acether, Faseb J. 2:A1377 (Abs), 1988 a.Google Scholar
  28. Korth, R., Hirafuji, M. and Benveniste, J. Comparison of human endothelial cells in culture and platelets for 3H-paf-acether binding. Fed Proc. 46:444 (Abs), 1987.Google Scholar
  29. Korth, R., Hirafuji, M., Lalau Keraly, C., Delautier, D., Bidault, J. and Benveniste, J. Interaction of the paf-acether antagonist WEB 2086 and its analogues (hetrazepines) with human platelets and endothelial cells. Brit. J. Pharmacol in press, 1988 b.Google Scholar
  30. Korth, R., Nunez, D., Bidault, J. and Benveniste, J. Comparison of three paf-acether receptor antagonist ginkgolides. Eur. J. Pharmacol. 152:101, 1988c.CrossRefGoogle Scholar
  31. Korth, R., Riess, H., Brehm, G. and Hiller, E. Unsaturated platelet- activating factor: influence on aggregation, serotonin release and thromboxane synthesis of human thrombocytes. Thromb. Res. 41:699–706, 1986.PubMedCrossRefGoogle Scholar
  32. Kramer, R.M., Jakubowski, J.J. and Deykin, D. Hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, a common precursor of platelet-activating factor and eicosanoids, by human platelet phospholipase A2. Biochim. Biophys. Acta. 959:269–279, 1988.PubMedCrossRefGoogle Scholar
  33. Kramer, R.M., Patton, G.M., Pritzker, C.R. and Deykin, D. Metabolism of platelet-activating factor in human platelets. J. Biol. Chem. 289:13316–13320, 1984.Google Scholar
  34. Lachachi, H., Plantavid, M., Simon, M.F., Chap, H., Braquet, P. and Douste-Blazy, L. Inhibition of transmembrane movement and metabolism of platelet activating factor (paf-acether) by a specific antagonist BN 52021. Biochem. Biophys. Res. Comm. 132:460–466, 1985.PubMedCrossRefGoogle Scholar
  35. Lambrecht, G. and Parnham, M.J. Kadsurenone distinguishes between different platelet-activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes. Br. J. Pharmacol. 87:287–289, 1986.PubMedCrossRefGoogle Scholar
  36. Lalau Keraly, C., Delautier, D., Delabassee, D., Chignard M. and Benveniste, J. Inhibition by ticlopidine of paf-acether-induced in vitro aggregation of rabbit and human platelets. Thromb. Res. 34:463–471, 1984.PubMedCrossRefGoogle Scholar
  37. Lee, T.C., Malone, B., Wassermann, S.I., Fitzgerald, V. and Snyder, F. Activities of enzymes that metabolize platelet-activating factor (1–0-alkyl-2-acetyl-sn-grycero-3-phosphocholine) in neutrophils and eosinophils from humans and the effect of calcium ionophore. Biochem. Biophys. Res. Commun. 105:1303–1308, 1982.PubMedCrossRefGoogle Scholar
  38. Mclntyre T.M., Zimmerman, G.A., Satoh, K. and Prescott, S.M. Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin and adenosine triphosphate. J. Clin. Invest. 76:271–280, 1985.CrossRefGoogle Scholar
  39. Mclntyre, T.M., Zimmerman, G.A. and Prescott, S.M. Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. Proc. Natl. Acad Sci. USA. 83:2204–2208, 1986.CrossRefGoogle Scholar
  40. Morrison, W.J. and Shukla, S.D. Desensitization of receptor-coupled activation of phosphoinositide-specific phospholipase C in platelets: Evidence for distinct mechanisms for platelet-activating factor and thrombin. Mol. Pharmacol. 33:55–63, 1988.Google Scholar
  41. Ninio, E. Regulation of platelet-activating factor biosynthesis in various cell types. In New horizons in platelet activating factor research. ed. by C.M. Winslow and M.L. Lee, John Wiley and Sons Ltd., New York, 1987.Google Scholar
  42. Nunez, D., Chignard, M., Korth, R., Le Couedic, J.P., Norel, X., Spinnewyn, B., Braquet, P. and Benveniste, J. Specific inhibition of paf-acether-induced platelet activation by BN 52021 and comparison with the paf-acether inhibitors Kadsurenone and CV 3988. Eur. J. Pharmacol. 123:197–205, 1986.PubMedCrossRefGoogle Scholar
  43. O’Flaherty, J.R., Jefferson, R.S., Redman, J., Jacobsen, D., Piantadosi, C. and Wykle, R.M. Binding and metabolism of platelet-activating factor by human neutrophils. J. Clin. Invest. 78:381–388, 1986.PubMedCrossRefGoogle Scholar
  44. Okayasa, T., Hoshii, K., Seyama, K., Ishibashi, T. and Imai, Y. Metabolism of platelet-activating factor in primary cultured adult rat hepatocytes by a new pathway involving phospholipase C and alkyl monooxygenase. Biochim. Biophys. Acta. 876:58–64, 1986.CrossRefGoogle Scholar
  45. Pieroni, G. and Hanahan, D.J. Metabolic behaviour of acetyl glyceryl ether phosphoryl-choline on interaction with rabbit platelets. Arch. Biochem. Biophys. 224:485–493, 1983.PubMedCrossRefGoogle Scholar
  46. Pinckard, R.N., McManus, M. and Hanahan, D.J. Chemistry and biology of acetyl glyceryl ether phosphorylcholine (platelet-activating factor). Advances in in flamm. research 4:. 147–178, 1982.Google Scholar
  47. Prescott, S.M., Zimmerman, G.A. and Mcintyre, T.M. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc. Natl. Acad. USA. 81:3534–3538, 1984.CrossRefGoogle Scholar
  48. Scatchard, G. Attraction of proteins for small molecules and ions. Ann. NY. Acad Sci. 51:660–672, 1949.CrossRefGoogle Scholar
  49. Shen, T.Y., Hwang, S.B., Chang, N.M., Doebber, T.W., Lam, M.H.T., Wu, M.S., Wang, X., Han, O.Q. and Li, R.Z. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura):Specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. Proc. Natl. Acad Sci. USA. 82:672–677, 1985.PubMedCrossRefGoogle Scholar
  50. Snyder, F. Chemical and biochemical aspects of platelet activating factor: a novel class of acetylated ether-linked choline phospholipids. Med Res. Rev. 5:107–140, 1985.PubMedCrossRefGoogle Scholar
  51. Stafforini, D.M., Mcintyre, T.M., Carter, M.E. and Prescott, S.M. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262:4215–4222, 1987.PubMedGoogle Scholar
  52. Stafforini, D.M., Prescott, S.M. and Mcintyre, T.M. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 262:4223–4230, 1987.PubMedGoogle Scholar
  53. Suzuki, Y., Miwa, M., Harada, M. and Matsumoto, M. Release of acetylhydrolase from platelets on aggregation with platelet-activating factor. Eur. J. Biochem. 172:117–120, 1988.PubMedCrossRefGoogle Scholar
  54. Terashita, Z.I., Tsushima, S., Yoshioka, Y., Nomura, H., Inada, Y. and Nishikawa, K. CV 3988 a specific antagonist of platelet-activating factor (PAF). Life Sciences. 32:1975–1982, 1983.PubMedCrossRefGoogle Scholar
  55. Thornton S.C., Mueller, S.N. and Levine, E.M. Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science (Wash. D.C.). 222:623–625, 1983.CrossRefGoogle Scholar
  56. Touqui, L., Jacquemin, C. and Vargaftig, B.B. Conversion of 3H-paf-acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite. Biochem. Biophys. Res. Commun. 110:890–893, 1983.PubMedCrossRefGoogle Scholar
  57. Valone, F.H. Identification of platelet-activating factor receptors in p 388 D1 murine macrophages. J. Immunol. 140:2389–2394, 1988.PubMedGoogle Scholar
  58. Valone F.H., Coles, E., Reinhold, V.R. and Goetzl, E.J. Specific binding of phospholipid platelet-activating factor by human platelets. J. Immunol. 129:1637–1641, 1982.PubMedGoogle Scholar
  59. Valone F.H. and Goetzl, E.J. Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1–0-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphocholine. Immunology. 48:141–149, 1983.PubMedGoogle Scholar
  60. Vargaftig, B.B., Chignard, M., Benveniste, J., Lefort, J. and Wal, F. Background and present status of research on platelet-activating factor (PAF-acether). N.Y. Acad. Sci. 370:119–137, 1981.CrossRefGoogle Scholar
  61. Wade, P.J., Lunt, D.O., Lad, N., Tuffin, D.P. and Mccullagh, K.G. Effect of calcium and calcium antagonists on 3H-paf-acether binding to washed human platelets. Thromb. Res. 41:251–262, 1986.PubMedCrossRefGoogle Scholar
  62. Wardlow, M.L., Cox, C.P., Meng, K.E., Greene, D.E. and Farr, R.S. Substrate specifity and partial characterization of the paf acylhydrolase in human serum that rapidly inactivates platelet-activating factor. J. Immunol. 136:3441–3446, 1986.PubMedGoogle Scholar
  63. Whatley, R.E., Zimmermann, G.A., Mclntyre, T.M. and Prescott, S.M. Endothelium from diverse vascular sources synthesizes platelet-activating factor. Arteriosclerosis. 8:321–331, 1988.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Ruth Korth
    • 1
  • M. Hirafuji
    • 3
  • J. Bidault
    • 1
  • B. Canton
    • 2
  • F. Russo-Marie
    • 2
  • J. Benveniste
    • 1
  1. 1.INSERM U 200Universite de Paris SudClamartFrance
  2. 2.INSERM U 285Unité associée Institut PasteurParisFrance
  3. 3.Dental University of TohokuSendaiJapan

Personalised recommendations